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lung cancer confined to a single lung lobe: a case
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Background: The outcomes of video-assisted thoracic bronchial sleeve lobectomy (VABSL), a minimally invasive
video-assisted thoracoscopic (VATS) lobectomy, are mostly unknown in Chinese patients.
Objectives: To investigate operative and postoperative outcomes of VABSL in a cases series of Chinese patients
with lung cancer.
Methods: Retrospective study of 9 patients (male:female 8:1; mean age 59.4 ± 17.6 years, ranging 21–79 years)
diagnosed with lung cancer of a single lobe, treated with VABSL between March 2009 and November 2011, and
followed up for at least 2 months (mean follow-up: 14.17 ± 12.91 months). Operative outcomes (tumor size, operation
time, estimated blood loss and blood transfusion), postoperative outcomes (intensive care unit [ICU] stay, hospitalization
length and pathological tumor stage), death, tumor recurrence and safety were assessed.
Results: Patients were diagnosed with carcinoid cancer (11.1%), squamous carcinoma (66.7%) or small cell carcinoma
(22.2%), affecting the right (77.8%) or left (22.2%) lung lobes in the upper (55.6%), middle (11.1%) or lower (33.3%)
regions. TNM stages were T2 (88.9%) or T3 (11.1%); N0 (66.7%), N1 (11.1%) or N2 (22.2%); and M0 (100%). No patient
required conversion to thoracotomy. Mean tumor size, operation time and blood loss were 2.50 ± 0.75 cm, 203 ±
20 min and 390 ± 206 ml, respectively. Patients were treated in the ICU for 18.7 ± 0.7 hours, and overall hospitalization
duration was 20.8 ± 2.0 days. No deaths, recurrences or severe complications were reported.
Conclusions: VABSL surgery is safe and effective for treatment of lung cancer by experienced physicians, warranting
wider implementation of VABSL and VATS training in China.
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In modern thoracic surgery, anatomically suitable central
lung cancers are commonly treated by sleeve lobectomy,
regardless of lung function [1]. However, there has been
a wide implementation of video-assisted thoracoscopic
(VATS) lobectomy for performing bronchial sleeve lobec-
tomy (VABSL), an approach that is minimally invasive,
more technically challenging [2], and with good outcomes
[3,4]. In the Unites States and Europe, only 20-30% of all* Correspondence: liuzhidongmedsci@163.com
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reproduction in any medium, provided the orlobectomies are performed using VATS, but this proportion
is rapidly rising [2] and new training programs are being
implemented [5]. In China, the number of lobectomies per-
formed using VATS remains unknown, as there have been
very few published reports in lung cancer patients [6-8].
The use of bronchial anastomosis is the primary feature
that distinguishes VABSL from VATS lobectomy [9]. In
most cases, bronchial anastomosis is accomplished using
an open surgical technique through a mini-thoracotomy
with conventional open surgical instruments, although the
recent adoption of video-assistance and robotic surgery
has improved the outcomes of these procedures [10].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and VABSL have some advantages, including smaller inci-
sions, decreased postoperative pain and shorter hospital
stays [9,11]. Thus, VABSL is an effective alternative to
thoracotomy for many patients with lung cancer.
The present study retrospectively reviewed nine Chinese
lung cancer patients who were treated with VABSL. Our
findings provide evidence that VABSL may be effective and
safe for Chinese patients with lung cancer by reducing
bleeding, hospitalization time and complication rate, com-
pared with conventional open lobectomy and thoracotomy.
Methods
Patients
A total of 9 patients, diagnosed with squamous carcinoma,
small cell carcinoma, or carcinoid cancer of a single lung
lobe, were treated with VABSL between March 2009 and
November 2011 at the Beijing Chest Hospital, Beijing,
People’s Republic of China (Table 1). No patient had a his-
tory of thoracotomy. The study protocol was approved by
the Ethics Committee of the Beijing Chest Hospital
(Beijing, People’s Republic of China). All patients provided
written informed consent.
Operative procedure
All thoracic surgeons were trained and experienced in
VABSL. The decision to perform VABSL was based on sur-
geons’ preference, intraoperative assessment of adhesions
and calcifications adjacent to pulmonary branches, and pre-
operative computed tomography (CT) [12]. Mediastinos-
copy was performed in all patients to exclude a N2 disease.
Patients were placed in prone position. Endoshears/
Endokittners (US Surgical, Norwalk, CT, USA) were
used for dissection, and thoracic bronchial sleeve lob-
ectomy was performed through four 1-cm thoracic
ports. Pulmonary artery and vein branches were di-
vided using an EndoGIA vascular stapler (U.S. Surgical,
Norwalk, CT, USA). Bronchus was divided usingTable 1 Patients included in the study
No. Age (yr) Sex Diagnosis Site
Side Pos
1 56 M Squamous carcinoma R
2 70 M Squamous carcinoma R
3 46 M Small cell carcinoma R
4 68 M Squamous carcinoma R
5 73 M Small cell carcinoma R
6 79 M Squamous carcinoma L
7 56 M Squamous carcinoma R
8 66 M Squamous carcinoma L
9 21 F Carcinoid cancer R
Abbreviations: R, right; L, left; u, upper; m, middle; l, lower.scissors. Bronchial anastomosis was performed, and le-
sions were directly palpated through the utility incision
without trocar use (except for the camera port). In the
early surgeries, discontinuous anastomosis was per-
formed using 3–0 absorbable suture to discontinuously
suture the whole layer: the less exposed tracheal wall
was sutured and the anterior tracheal wall was anasto-
mosed first, and prepositioned silk was ligated and su-
tured from the tracheal cartilage. In the late surgeries,
continuous anastomosis combined with discontinuous
consolidation was performed using 3–0 absorbable su-
ture to first anastomose the less exposed tracheal wall
and the anterior tracheal wall. Anastomosis was con-
tinuously sutured for about 1/3 of the whole cycle
when the two ends of the suture were fixed, followed
by continuous suture for 1/3 and 1/3 cycles from the
two fixed ends respectively. If an air leak was observed,
discontinuous suture and repair were performed using
3–0 absorbable suture.
The entire operation was performed with conventional
long instruments, as previously described [9]. Consider-
ations were made for the anatomical position of the le-
sion for each patient.
Freed lobes were placed in an Endocatch bag (U.S.
Surgical, Norwalk, CT, USA). The chest was irrigated, and
the anastomosis checked for leakage. Two 28 F chest tubes
were placed, and the incisions were closed. Postoperative
bronchoscopy was performed to clear blood and secre-
tions from the airways prior to extubation, as well as to
observe the healing of the anastomotic stoma and the
eventual occurrence of fistula and stenosis [9].
Tumor size, operation time, estimated blood loss
and blood transfusion requirement were assessed for
each patient.
Postoperative assessments
Immediately following surgery, each patient was kept in
the intensive care unit (ICU) until stable, and thenTNM stage Follow-up (mo) Recurrence
ition T N M
u 2 0 0 22 0
u 2 0 0 3.5 0
l 2 1 0 9 0
u 3 0 0 43 0
u 2 0 0 18 0
l 2 2 0 >3 0
m 2 2 0 11 0
u 2 0 0 >2 0
l 2 0 0 16 0
Table 2 Baseline demographic and clinical characteristics
Characteristic Value




Prior thoracotomy# 0 (0%)
TNM stage#
T2 8 (88.9%)
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ICU stay and the total duration of the hospital stay (as
an in-patient) were recorded.
Follow-up
Patients were followed up for a minimum of 2 months
after surgery (mean follow-up: 14.2 ± 12.9 months). All pa-
tients underwent at least one clinical examination more
than 1 month after surgery. The occurrence of death,





Follow-up time (months)* 14.2 ± 12.9 (2–43)
Diagnosis#
Carcinoid cancer 1 (11.1%)
Squamous carcinoma 6 (66.7%)







*Data are presented as the mean ± SD (range).
#Data are presented as n (%), where n is the number of patients (N = 9).
Table 3 Operative assessments
Assessment Value
Type of resection#
Right upper lobe 4 (44.4%)
Right middle lobe 1 (11.1%)
Right lower lobe 2 (22.2%)
Left upper lobe 1 (11.1%)
Left lower lobe 1 (11.1%)
Tumor size (cm)* 2.50 ± 0.75
Estimated blood loss (ml)* 390 ± 206
Operation time (min)* 203 ± 20
Blood transfusion (ml)* 133.3 ± 200.0
*Data are presented as the mean ± SD.
#Data are presented as n (%), where n is the number of patients (N = 9).Results
Patients’ demographic and clinical characteristics
Patients (N = 9) had a mean age of 59.4 ± 17.6 years, ran-
ging from 21 to 79 years. Most patients (8/9, 88.9%) were
male. On final pathological examination, patients were di-
agnosed with carcinoid cancer (1/9, 11.1%), squamous car-
cinoma (6/9, 66.7%) or small cell carcinoma (2/9, 22.2%),
affecting the right (7/9, 77.8%) or left (2/9, 22.2%) lung
lobes. However, the two cases of small cell carcinoma were
initially diagnosed as poorly differentiated squamous car-
cinomas on preoperative biopsy. The lesions were posi-
tioned in the upper, middle and lower lobe regions in 5
(55.6%), 1 (11.1%), and 3 (33.3%) patients, respectively. In
all patients, preoperative mediastinoscopy indicated an ab-
sence of local metastasis. In addition, no patient had a
history of neoadjuvant treatments or thoracotomy. Final
pathological TNM staging was: T2 (8/9, 88.9%) and T3
(1/9, 11.1%); N0 (6/9, 66.7%), N1 (1/9, 11.1%), and N2
(2/9, 22.2%); and M0 (9/9, 100%) (Tables 1 and 2).
Operative characteristics
Conversion to open thoracotomy was not required for any
patient. Resection of the right upper lung lobe was the
most common (4/9, 44.4%), followed by the right lower
lobe (2/9, 22.2%). The mean tumor size was 2.50 ±
0.75 cm. The duration of surgery was 203 ± 20 min, with
an estimated blood loss of 390 ± 206 ml. Blood transfu-
sions were required in 3 patients (Table 3).
Histology and final pathologic tumor stage
The most common histological type was squamous car-
cinoma. Pathological tumor stage was determined to be
IB in 6 (66.7%) patients, IIA in 1 (11.1%) patient and
IIIA in 2 (22.2%) patients. Stage IB was thus the most
common pathological stage (Table 4).
Post-operative and follow-up outcomes
Immediately after surgery, patients stayed in the ICU
for a mean of 18.7 ± 0.7 hours before being transferred
to normal in-patient facilities. The total duration of
hospitalization lasted, on average, 20.8 ± 2.0 days. During
hospitalization, pain was effectively treated using routinemedication, and no complication due to drainage tube
placement or removal was observed. No deaths or severe
adverse events were reported during hospitalization or the
follow-up period. Furthermore, no patient exhibited recur-
rence or required secondary surgery (Table 5).









Carcinoid – typical 1 (11.1%)
Squamous 6 (66.7%)
Small cell carcinoma 2 (22.2%)
Data are presented as n (%), where n is the number of patients (N = 9).
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VABSL was successfully used to treat lung cancer without
short-term occurrence of metastasis, cancer recurrence, or
death in nine patients. Furthermore, all complications and
adverse events (such as pain) were mild, and were treated
using routine medications. In addition, bleeding and
hospitalization duration were minimal, with no cases of
excessive bleeding or drainage. Thus, VABSL may be a
valuable, minimally invasive method for the treatment of
many different forms of lung cancer in Chinese patients,
although adequate thoracic surgeon training and experi-
ence may be required to achieve optimal results.
There are controversies about the complication rates as-
sociated with the use of VABSL, and how these rates com-
pare with those of open surgery. Indeed, various studies
worldwide have reported highly variant hospitalization re-
quirements and costs. In a study conducted in the United
States, Mahtabifard et al. [9] reported that a large propor-
tion of patients undergoing VABSL experienced severe
complications (15.4%), including edema, stricture of the
anastomosis site requiring airway stenting, and anasto-
motic dehiscence. Similarly, Belgers et al. [13] reported that
10% of 172 patients treated with VATS in the Netherlands
experienced complications. A study in Spain also reported
a similar complication rate (12.8%), mostly due to air leak-
age [14]. Conversely, a study of 362 lung resection cases in
Japan using VABSL reported a median postoperativeTable 5 Postoperative and follow-up outcomes
Assessment Value
ICU stay (hours)* 18.7 ± 0.7
Hospitalization (days)* 20.8 ± 2.0
Recurrence# 0 (0%)
Death# 0 (0%)
Adverse events# 0 (0%)
*Data are presented as the mean ± SD.
#Data are presented as n (%), where n is the number of patients (N = 9).hospital stay of only seven days, without major postopera-
tive complications [15]. A single-center Israeli study con-
ducted by Arad et al. [16] suggested that the complication
rate decreased after the first 6 months of VATS implemen-
tation, indicating that surgeon’s experience was involved in
obtaining good outcomes.
In the present study, no severe complications were
observed and the mean hospitalization duration was
20.8 ± 2.0 days. These discrepancies may be due to the
selection of the operative field [15] or experience with
the technique [16]. Furthermore, video-assisted surgery
for lung cancer has been shown to produce dramatically
shorter hospitalization duration than conventional open
surgery [14]. These findings were confirmed on a much
larger scale by the American College of Surgeons On-
cology Group Z0030 trial that included 964 partici-
pants, and demonstrated that the majority of patients
treated with VATS exhibited shorter hospital stays and
fewer complications than patients undergoing open sur-
gery [17]. Although VATS and VABSL have been less
studied in China, Li and Wang have published two re-
ports describing the successful use of VABSL with
bronchoplasty in Chinese patients, with only one pa-
tient in their cohort of 10 [7] and 15 [8] experiencing
minor complications. A recent review by Zhang et al.
[18] suggested that video-assisted thoracic lobectomy may
reduce cancer recurrence and result in better overall sur-
vival compared with conventional open thoracotomy for
non-small-cell lung cancer patients. Thus, VABSL is
clearly superior to open surgery for eligible patients, and is
increasingly being implemented worldwide as a treatment
for lung cancer. However, better standardization will be
required as VATS and VABSL become increasingly imple-
mented as routine lung cancer strategies, in order to
achieve better consistency of treatment outcomes.
One of the central benefits of VATS surgery over open
lobectomy is that bleeding is minimized, thereby reducing
fluid drainage and subsequent complications involving
edema or bleeding in the pleural cavity [19]. In fact, VATS
has been suggested as a tool for alleviation of bleeding in
other conditions, such as spontaneous hemopneumothorax,
due to its effectiveness at not only reducing, but also elim-
inating bleeding in the pleural cavity [20]. In the study by
Belgers et al. [13], which reported a relatively high compli-
cation rate for VATS, the mean blood loss was 444 ml and
the mean operating time was 179 min. It is important to
note that the lower level of bleeding in the present study
(390 ± 206 ml) may have contributed to the overall good
outcomes and low complication rate. These findings may
also be related to the comparatively short mean operating
time of 203 ± 20 min, which may be the result of more ex-
perienced or better trained surgeons. However, when ac-
counting for the time lost for adjusting surgical focus,
stabilization and modulation of the monitors, our patients
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bleeding may vary between VATS methods, a recent meta-
analysis reported that bleeding was not significantly differ-
ent between open surgery and VATS. However, in each
case, mortality, morbidity, air leakage, pneumonia, sepsis
and atrial arrhythmias were reduced in patients receiving
VATS compared with those who underwent open surgery.
Although the amount of bleeding caused by VABSL is
highly variable, the overall outcomes are consistently better
than those observed with open surgery.
Although discontinuous anastomosis is reliable, the su-
ture was often ligated in the tracheal lumen, which caused
postoperative sputum stagnation and irritable cough. In
addition, since the handle hole under the thoracoscope is
limited, the operation was more difficult with longer surgi-
cal time. In contrast, continuous anastomosis combined
with discontinuous consolidation avoided the presence of
absorbable suture in the tracheal lumen, therefore de-
creasing postoperative sputum stagnation and irritable
cough; it also decreased the anastomosis time.
In general, lower mortality has been observed in patients
undergoing modern VABSL procedures compared with
those undergoing conventional open surgery. Loscertales
et al. [14], using 17 recent studies, concluded that patients
undergoing VATS lobectomy experienced less postopera-
tive pain, reduced chest tube time, and overall better out-
comes, including reduced mortality, than open surgery
patients. Mahtabifard et al. [9] also reported lower mor-
tality in patients undergoing VABSL. Furthermore, a
meta-analysis of 21 studies (2 randomized and 19 non-
randomized) indicated that VATS surgery resulted in
lower 5-year all-cause mortality, as well as lower recur-
rence rates [21], consistent with the low mortality and
recurrence observed in the present study. Cumulatively,
the present findings and previous research indicate that
VABSL provides superior long-term outcomes and limits
lung cancer recurrence, perhaps even more effectively
than conventional open surgery. Thus, we recommend the
wider implementation of VABSL in China in patients with
lung cancer who are deemed suitable for lobectomy with
bronchoplasty.
The evidence-based clinical practice guidelines of the
American College of Chest Physicians recently suggested
that “In patients with stage I NSCLC who are considered
appropriate candidates for thoracoscopic anatomic lung
resection (lobectomy or segmentectomy), the use of VATS
by surgeons experienced in these techniques is an accept-
able alternative to open thoracotomy” [9], consistent with
our current recommendations. While operator experience
is a key factor to surgical success of VATS and VABSL,
guidelines for junior surgeons (<100 surgeries performed)
have been recently proposed in Korea and indicate that
the VATS lobectomy technique can be dramatically im-
proved over the course of only 6 months. Thereafter,junior surgeons reported similar conversions to open sur-
gery and outcomes as experienced surgeons [22]. Similarly,
European VATS training programs have been designed,
and showed that prolonged air leak, chest tube duration,
operation time and length of stay were reduced by training,
most likely due to superior patient selection by trained op-
erators [23,24]. As VATS and VABSL are technically chal-
lenging procedures that have been demonstrated to be
more successful when performed by specially-trained thor-
acic surgeons, it has been suggested that training for these
procedures should be coordinated at a national level as they
become more widely implemented [24]. It may be benefi-
cial to consider implementing similar national training
and patient eligibility determination in China, though fur-
ther research will be required to determine the optimal
parameters in Chinese clinical practice settings.
It is important to consider that the present results were
obtained from a relatively small and non-diverse patient
population of only 9 predominantly male cases. Thus, these
findings may not be typical of the general population of
Chinese lung cancer patients. Similarly, the surgeons in the
present study were both trained and experienced, and less
qualified surgeons may experience poorer results and a
greater need for intraoperative conversion to open surgery,
further highlighting the need for additional standardization
and regulation of training in VATS techniques in China.
Additionally, VABSL may be less effective for more ad-
vanced cancer stages where lymph nodes infiltration has
occurred. Further research should be conducted to validate
these findings in larger clinical populations with more di-
verse presentations of lung cancer.
Conclusions
The present results provide preliminary evidence that
VABSL is both safe and effective for the treatment of lung
cancer in Chinese patients, consistent with previous reports
worldwide. Furthermore, VABSL may minimize complica-
tion rates when used by trained and experienced thoracic
surgeons, resulting in less bleeding, lower recurrence rates,
and better overall outcomes than conventional open lobec-
tomy surgery. Thus, we recommend that VATS and VABSL
should be more widely implemented in China, along with
appropriate, nationally-regulated training programs.
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